You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLorcaserin
Accession NumberDB04871
TypeSmall Molecule
GroupsApproved
Description

Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride.

Structure
Thumb
Synonyms
Lorqess
External Identifiers
  • APD-356
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Belviqtablet10 mg/1oralEisai Inc.2012-06-27Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LorqessNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Lorcaserin hydrochloride
846589-98-8
Thumb
  • InChI Key: ITIHHRMYZPNGRC-QRPNPIFTSA-N
  • Monoisotopic Mass: 231.058154899
  • Average Mass: 232.15
DBSALT000111
Lorcaserin hydrochloride hemihydrate
ThumbNot applicableDBSALT001583
Categories
UNII637E494O0Z
CAS number616202-92-7
WeightAverage: 195.69
Monoisotopic: 195.0814772
Chemical FormulaC11H14ClN
InChI KeyXTTZERNUQAFMOF-QMMMGPOBSA-N
InChI
InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1
IUPAC Name
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
SMILES
C[[email protected]]1CNCCC2=CC=C(Cl)C=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassNot Available
Direct ParentBenzazepines
Alternative Parents
Substituents
  • Benzazepine
  • Azepine
  • Aralkylamine
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Secondary amine
  • Secondary aliphatic amine
  • Azacycle
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Organic nitrogen compound
  • Amine
  • Hydrocarbon derivative
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.
PharmacodynamicsLorcaserin produced a dose-dependent weight loss over a 12-week period by promoting satiety and decreasing food consumption.
Mechanism of actionAlthough the exact mechanism is unknown, it is believed to involve the selective activation of 5-HT2C receptors in the anorexigenic pro-opiomelanocortin neurons in the arcuate nucleus of the hypothalamus. This results in decreased food intake and satiety by promoting the release of alpha-melanocortin stimulating hormone, which acts on melanocortin-4 receptors.
Related Articles
AbsorptionLorcaserin has a peak plasma concentration of about 1.5 - 2 hours, but the bioavailability was not determined.
Volume of distribution

The volume of distribution was not determined, but lorcaserin distributes to the central nervous system and cerebrospinal fluid.

Protein bindingLorcaserin hydrochloride has a plasma protein binding of approximately 70%.
Metabolism

Lorcaserin has extensive hepatic metabolism producing inactive compounds. Lorcaserin sulfamate (M1) is the major metabolite circulating in the plasma, and N-carbamoyl glucuronide lorcaserin (M5) is the major metabolite in urine. Other minor metabolites that are both excreted in urine are glucuronide or sulfate conjugates.

SubstrateEnzymesProduct
Lorcaserin
Not Available
Lorcaserin sulfamateDetails
Lorcaserin
Not Available
N-carbamoyl glucuronide lorcaserinDetails
Route of eliminationLorcaserin is eliminated by hepatic metabolism, and the metabolites are eliminated mostly in the urine (92.3%) and some through feces (2.2%).
Half lifeThe plasma half life is approximately 11 hours.
Clearance

The clearance value was not determined.

ToxicityMost common adverse reactions include hypoglycemia (diabetic patients), headache, back pain,fatigue, decrease in lymphocytes,upper respiratory tract infection, and nasopharyngitis. Moreover, the safety and efficacy of coadministration with other weight loss products has not been established, and cardiovascular effects on mortality and morbidity have not been established.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6953787 No2003-04-102023-04-10Us
US7514422 No2003-04-102023-04-10Us
US7977329 No2003-04-102023-04-10Us
US8168624 No2009-04-182029-04-18Us
US8207158 No2003-04-102023-04-10Us
US8273734 No2003-04-102023-04-10Us
US8367657 No2003-04-102023-04-10Us
US8546379 No2003-04-102023-04-10Us
US8575149 No2003-04-102023-04-10Us
US8697686 No2005-12-202025-12-20Us
US8946207 No2004-06-162024-06-16Us
US8980881 No2005-12-202025-12-20Us
US8999970 No2013-02-072033-02-07Us
US9169213 No2012-12-062032-12-06Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityWater solubility is greater than 400 mg/mL.From FDA label.
Predicted Properties
PropertyValueSource
Water Solubility0.0709 mg/mLALOGPS
logP3ALOGPS
logP2.83ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)10.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity56.65 m3·mol-1ChemAxon
Polarizability21.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Jandacek RJ: APD-356 (Arena). Curr Opin Investig Drugs. 2005 Oct;6(10):1051-6.

General References
  1. Halford JC: Obesity drugs in clinical development. Curr Opin Investig Drugs. 2006 Apr;7(4):312-8. [PubMed:16625817 ]
  2. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Dosa PI, Covel JA, Ren A, Webb RR, Beeley NR, Martin M, Morgan M, Espitia S, Saldana HR, Bjenning C, Whelan KT, Grottick AJ, Menzaghi F, Thomsen WJ: Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem. 2008 Jan 24;51(2):305-13. Epub 2007 Dec 21. [PubMed:18095642 ]
External Links
ATC CodesA08AA11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (401 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcepromazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Acetophenazine.
AmisulprideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Amisulpride.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lorcaserin.
AvanafilThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Avanafil.
BenzquinamideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Benzquinamide.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Lorcaserin.
BromocriptineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Bromocriptine.
BupropionBupropion may increase the serotonergic activities of Lorcaserin.
CabergolineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Cabergoline.
CarphenazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Carphenazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Chlorprothixene.
ClozapineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Clozapine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Lorcaserin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Lorcaserin.
DihydroergotamineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Dihydroergotamine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Lorcaserin.
DroperidolThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Droperidol.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Lorcaserin.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergotamine.
FencamfamineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fencamfamine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lorcaserin.
FlupentixolThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fluspirilene.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Lorcaserin.
GranisetronGranisetron may increase the serotonergic activities of Lorcaserin.
HaloperidolThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Haloperidol.
LoxapineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Loxapine.
MesoridazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Mesoridazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Methotrimeprazine.
MetoclopramideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Lorcaserin.
MolindoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Molindone.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Lorcaserin.
OlanzapineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Olanzapine.
OndansetronThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ondansetron.
PaliperidoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Paliperidone.
PerphenazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Perphenazine.
PimozideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Piperacetazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Promazine.
PropafenoneThe serum concentration of Lorcaserin can be increased when it is combined with Propafenone.
QuetiapineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Quetiapine.
RemoxiprideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Risperidone.
SertindoleThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sertindole.
SildenafilThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sildenafil.
SulpirideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sulpiride.
TadalafilThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Tadalafil.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Lorcaserin resulting in a loss in efficacy.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Lorcaserin.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lorcaserin.
ThiothixeneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Thiothixene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lorcaserin.
TrifluoperazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Triflupromazine.
VardenafilThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Vardenafil.
ZiprasidoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ziprasidone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Zuclopenthixol.
Food Interactions
  • Administration with or without food has no effect.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Halford JC: Obesity drugs in clinical development. Curr Opin Investig Drugs. 2006 Apr;7(4):312-8. [PubMed:16625817 ]
  2. Jandacek RJ: APD-356 (Arena). Curr Opin Investig Drugs. 2005 Oct;6(10):1051-6. [PubMed:16259227 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Nadp binding
Specific Function:
This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. Form I catalyzes the N-oxygenation of secondary and tertiary amines.
Gene Name:
FMO1
Uniprot ID:
Q01740
Molecular Weight:
60310.285 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Comments
comments powered by Disqus
Drug created on October 20, 2007 04:39 / Updated on June 26, 2016 01:53